Weekly Recap | Bristol Myers Squibb +1.07%, multiple Phase 3 wins
I'm LongbridgeAI, I can summarize articles.Bristol Myers Squibb (BMY) gained 1.07% this week to close at $59.75, while the S&P 500 fell 1.95%, leaving the stock about 3.02 percentage points ahead of the benchmark. The week opened strongly, touched a high of $62.25, then pulled back to a low of $56.15 on Tuesday before steadying across the final three sessions. Weekly range was 10.15%, with turnover running roughly 60% above the 60-day median.
The Week
Bristol Myers Squibb (BMY) gained 1.07% this week to close at $59.75, while the S&P 500 fell 1.95%, leaving the stock about 3.02 percentage points ahead of the benchmark. The week opened strongly, touched a high of $62.25, then pulled back to a low of $56.15 on Tuesday before steadying across the final three sessions. Weekly range was 10.15%, with turnover running roughly 60% above the 60-day median.
Key Events
BMY delivered a string of positive Phase 3 readouts. On Monday, the ALOFT-IPF trial evaluating Admilparant in idiopathic pulmonary fibrosis met its primary endpoint. The same day, the company announced positive topline results from an interim analysis of the ACTION-1 study of RYZ101, a radiopharmaceutical therapy for GEP-NETs. The Zenbexus Phase 3 trial also validated benefit. The news lifted the stock more than 4% in pre-market trading, but dosing and safety concerns around Admilparant trimmed those gains. A company spokesperson said the patient death in the study was unrelated to the drug and involved a 120 mg dose. On Tuesday, Jefferies raised its price target from $73 to $76. By midweek, a rotation into defensive sectors supported pharma names, and BMY stabilised.
Analyst Ratings
Across 29 covering institutions, 10 rate the stock buy or over, 17 hold, 1 sell or under, and 1 has no opinion. The consensus rating is hold, with a consensus target of $65.625, about 9.8% above the latest price. The target range is wide, from $41 to $82. Within 203 pharmaceutical companies, BMY ranks second in industry rating rank.
The Week Ahead
BMY reports fiscal third-quarter earnings on 29 October before the market opens, with expectations around $0.95 EPS and $12.7 billion in revenue. Ahead of that, macro data such as the NAHB housing market index on 19 October, followed by housing starts and building permits, may shape broad market risk appetite.
In Short
BMY’s week was defined by positive clinical news and outperformance against a falling market, with price swings reflecting tension between pipeline diversification and lingering dose concerns. Valuation sits near 13x P/E with a 4.2% dividend yield and a strong industry ranking, but the consensus target offers only about 10% upside and broker targets remain widely spread. The next test is the third-quarter report and how the market digests the latest trial data.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.